Negative feedback regulation of the ERK1/2 MAPK pathway

The extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signalling pathway regulates many cellular functions, including proliferation, differentiation, and transformation. To reliably convert external stimuli into specific cellular responses and to adapt to environmental circumstances, the pathway must be integrated into the overall signalling activity of the cell. Multiple mechanisms have evolved to perform this role. In this review, we will focus on negative feedback mechanisms and examine how they shape ERK1/2 MAPK signalling. We will first discuss the extensive number of negative feedback loops targeting the different components of the ERK1/2 MAPK cascade, specifically the direct posttranslational modification of pathway components by downstream protein kinases and the induction of de novo gene synthesis of specific pathway inhibitors. We will then evaluate how negative feedback modulates the spatiotemporal signalling dynamics of the ERK1/2 pathway regarding signalling amplitude and duration as well as subcellular localisation. Aberrant ERK1/2 activation results in deregulated proliferation and malignant transformation in model systems and is commonly observed in human tumours. Inhibition of the ERK1/2 pathway thus represents an attractive target for the treatment of malignant tumours with increased ERK1/2 activity. We will, therefore, discuss the effect of ERK1/2 MAPK feedback regulation on cancer treatment and how it contributes to reduced clinical efficacy of therapeutic agents and the development of drug resistance.

[1]  U. Rapp,et al.  Active Ras induces heterodimerization of cRaf and BRaf. , 2001, Cancer research.

[2]  F. McCormick,et al.  Regulation of Epidermal Growth Factor Receptor Signaling by Phosphorylation of the Ras Exchange Factor hSOS1 (*) , 1996, The Journal of Biological Chemistry.

[3]  Hiroshi Sakaue,et al.  The Molecular Scaffold Kinase Suppressor of Ras 1 (KSR1) Regulates Adipogenesis , 2005, Molecular and Cellular Biology.

[4]  Philippe P Roux,et al.  RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation. , 2012, The Biochemical journal.

[5]  Julian Downward,et al.  EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2 , 1997, Oncogene.

[6]  E. Lees,et al.  Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1 , 1997, Molecular and cellular biology.

[7]  K. Flaherty,et al.  Elucidating distinct roles for NF1 in melanomagenesis. , 2013, Cancer discovery.

[8]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[9]  Nils Blüthgen,et al.  Strong negative feedback from Erk to Raf confers robustness to MAPK signalling , 2011, Molecular systems biology.

[10]  O. Abdel-Wahab,et al.  BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. , 2015, Cancer cell.

[11]  L. Wennogle,et al.  Novel C‐Raf phosphorylation sites: serine 296 and 301 participate in Raf regulation , 2005, FEBS letters.

[12]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[13]  Jodi Gureasko,et al.  Membrane-dependent signal integration by the Ras activator Son of sevenless , 2008, Nature Structural &Molecular Biology.

[14]  A. Borczuk,et al.  Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. , 2010, Carcinogenesis.

[15]  Jing Jiang,et al.  ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. , 2008, Cellular signalling.

[16]  D. Woods,et al.  Senescence of human fibroblasts induced by oncogenic Raf. , 1998, Genes & development.

[17]  U. Rapp,et al.  Isotype-specific functions of Raf kinases. , 1999, Experimental cell research.

[18]  M. Kohno,et al.  ERK pathway positively regulates the expression of Sprouty genes. , 2001, Biochemical and biophysical research communications.

[19]  S. Yagel,et al.  Expression and regulation of Sprouty-2 in the granulosa-lutein cells of the corpus luteum. , 2005, Molecular human reproduction.

[20]  S. Nelson,et al.  Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.

[21]  Jurgen Müller,et al.  Compartmentalization of the MAPK scaffold protein KSR1 modulates synaptic plasticity in hippocampal neurons , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  C. Price,et al.  Fibroblast growth factor‐2 regulation of sprouty and NR4A genes in bovine ovarian granulosa cells , 2011, Journal of cellular physiology.

[23]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[24]  J. Qin,et al.  Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase. , 2005, Molecular biology of the cell.

[25]  R. Seger,et al.  The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions , 2006, Growth factors.

[26]  D. Morrison,et al.  Integrating signals from RTKs to ERK/MAPK , 2007, Oncogene.

[27]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[28]  D. Morrison,et al.  Assay of Raf-1 activity. , 2002, Methods in enzymology.

[29]  P. Shaw,et al.  PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway , 2002, Oncogene.

[30]  D. Fell,et al.  Differential feedback regulation of the MAPK cascade underlies the quantitative differences in EGF and NGF signalling in PC12 cells , 2000, FEBS letters.

[31]  P. Bastiaens,et al.  Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate , 2007, Nature Cell Biology.

[32]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[33]  Victoria Sanz-Moreno,et al.  Ras Subcellular Localization Defines Extracellular Signal-Regulated Kinase 1 and 2 Substrate Specificity through Distinct Utilization of Scaffold Proteins , 2008, Molecular and Cellular Biology.

[34]  A. Ribas,et al.  Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. , 2011, Cancer research.

[35]  Henry C. Chang,et al.  KSR, a novel protein kinase required for RAS signal transduction , 1995, Cell.

[36]  David B Solit,et al.  Resistance to MEK Inhibitors: Should We Co-Target Upstream? , 2011, Science Signaling.

[37]  C. Sander,et al.  V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway , 2009, Proceedings of the National Academy of Sciences.

[38]  O. Chaika,et al.  Phosphorylation of the kinase suppressor of ras by associated kinases. , 1999, Biochemistry.

[39]  D. Schadendorf,et al.  Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Yoshimura,et al.  Mammalian Sprouty4 Suppresses Ras-Independent ERK Activation by Binding to Raf1 , 2003, Cell cycle.

[41]  Kun-Liang Guan,et al.  Mechanisms of regulating the Raf kinase family. , 2003, Cellular signalling.

[42]  D. Morrison,et al.  C-TAK1 regulates Ras signaling by phosphorylating the MAPK scaffold, KSR1. , 2001, Molecular cell.

[43]  P. Serup,et al.  Fgf9 signalling stimulates Spred and Sprouty expression in embryonic mouse pancreas mesenchyme. , 2011, Gene expression patterns : GEP.

[44]  W. Fantl,et al.  Regulation of the MAP kinase pathway by mammalian Ksr through direct interaction with MEK and ERK , 1998, Current Biology.

[45]  E. Nishida,et al.  Negative feedback loop in T‐cell activation through MAPK‐catalyzed threonine phosphorylation of LAT , 2004, The EMBO journal.

[46]  Y. Yazaki,et al.  Feedback regulation of mitogen-activated protein kinase kinase kinase activity of c-Raf-1 by insulin and phorbol ester stimulation. , 1994, The Journal of biological chemistry.

[47]  G. Ladds,et al.  Feedback activation of neurofibromin terminates growth factor-induced Ras activation , 2016, Cell Communication and Signaling.

[48]  M. Shibuya,et al.  Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1 , 2003, Nature Cell Biology.

[49]  R. Dickinson,et al.  Both Nuclear-Cytoplasmic Shuttling of the Dual Specificity Phosphatase MKP-3 and Its Ability to Anchor MAP Kinase in the Cytoplasm Are Mediated by a Conserved Nuclear Export Signal* , 2004, Journal of Biological Chemistry.

[50]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[51]  D. Morrison,et al.  Functional analysis of C‐TAK1 substrate binding and identification of PKP2 as a new C‐TAK1 substrate , 2003, The EMBO journal.

[52]  J. Downward,et al.  Murine Ksr interacts with MEK and inhibits Ras-induced transformation , 1998, Current Biology.

[53]  I. Lax,et al.  The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors. , 2002, Molecular cell.

[54]  Philip R. Cohen,et al.  PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.

[55]  D. Sacks,et al.  Protein scaffolds in MAP kinase signalling. , 2009, Cellular signalling.

[56]  J. Olefsky,et al.  Negative Feedback Regulation and Desensitization of Insulin- and Epidermal Growth Factor-stimulated p21ras Activation (*) , 1995, The Journal of Biological Chemistry.

[57]  O. Carugo,et al.  A Mek1–Mek2 heterodimer determines the strength and duration of the Erk signal , 2009, Nature Structural &Molecular Biology.

[58]  William Pao,et al.  Genetic predictors of MEK dependence in non-small cell lung cancer. , 2008, Cancer research.

[59]  Kazuhiro Aoki,et al.  Multiple Decisive Phosphorylation Sites for the Negative Feedback Regulation of SOS1 via ERK* , 2010, The Journal of Biological Chemistry.

[60]  M. Reth,et al.  Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf , 2003, Oncogene.

[61]  J. Parsons,et al.  Mitogen-Activated Protein Kinase Feedback Phosphorylation Regulates MEK1 Complex Formation and Activation during Cellular Adhesion , 2004, Molecular and Cellular Biology.

[62]  Ultan McDermott,et al.  Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. , 2008, Cancer research.

[63]  P. Mischel,et al.  Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway , 2011, PloS one.

[64]  Michael A. Davies,et al.  Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents , 2012, Clinical Cancer Research.

[65]  P. Gibbs,et al.  Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  S. Keyse,et al.  Dual-specificity MAP kinase phosphatases (MKPs) , 2013, The FEBS journal.

[67]  K. Takishima,et al.  Epidermal growth factor (EGF) receptor T669 peptide kinase from 3T3-L1 cells is an EGF-stimulated "MAP" kinase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[68]  N. Hacohen,et al.  sprouty Encodes a Novel Antagonist of FGF Signaling that Patterns Apical Branching of the Drosophila Airways , 1998, Cell.

[69]  P. Cohen,et al.  Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. , 1992, The Biochemical journal.

[70]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[71]  A. Brunet,et al.  Growth factor‐stimulated MAP kinase induces rapid retrophosphorylation and inhibition of MAP kinase kinase (MEK1) , 1994, FEBS letters.

[72]  T. Tan,et al.  DUSPs, to MAP kinases and beyond , 2012, Cell & Bioscience.

[73]  D. Bar-Sagi,et al.  Identification of the mitogen-activated protein kinase phosphorylation sites on human Sos1 that regulate interaction with Grb2 , 1996, Molecular and cellular biology.

[74]  J. Sweatt,et al.  Kinase Suppressor of Ras1 Compartmentalizes Hippocampal Signal Transduction and Subserves Synaptic Plasticity and Memory Formation , 2006, Neuron.

[75]  Weiguo Zhang,et al.  Regulation of lymphocyte development and activation by the LAT family of adapter proteins , 2009, Immunological reviews.

[76]  G. Rubin,et al.  Identification of Constitutive and Ras-Inducible Phosphorylation Sites of KSR: Implications for 14-3-3 Binding, Mitogen-Activated Protein Kinase Binding, and KSR Overexpression , 1999, Molecular and Cellular Biology.

[77]  Robert E. Lewis,et al.  The Molecular Scaffold KSR1 Regulates the Proliferative and Oncogenic Potential of Cells , 2004, Molecular and Cellular Biology.

[78]  N. Rosen,et al.  Tumor adaptation and resistance to RAF inhibitors , 2013, Nature Medicine.

[79]  P. Edwards,et al.  Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells , 2011, Science Signaling.

[80]  J. Fletcher,et al.  The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. , 1999, Seminars in cancer biology.

[81]  D. Morrison,et al.  Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling , 2009, Molecular and Cellular Biology.

[82]  H. Sakurai,et al.  Inverse correlation between Thr‐669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation , 2013, Cancer science.

[83]  D. Bar-Sagi,et al.  A Lipid-Anchored Grb2-Binding Protein That Links FGF-Receptor Activation to the Ras/MAPK Signaling Pathway , 1997, Cell.

[84]  Ming Zhou,et al.  Regulation of Raf-1 by direct feedback phosphorylation. , 2005, Molecular cell.

[85]  E. Nishida,et al.  Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway , 2002, Nature Cell Biology.

[86]  D. Bar-Sagi,et al.  Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer. , 2013, Surgery.

[87]  S. Keyse,et al.  Specific Inactivation and Nuclear Anchoring of Extracellular Signal-Regulated Kinase 2 by the Inducible Dual-Specificity Protein Phosphatase DUSP5 , 2005, Molecular and Cellular Biology.

[88]  M. Benezra,et al.  BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. , 2008, The Journal of clinical endocrinology and metabolism.

[89]  Muffy Calder,et al.  The Mammalian MAPK/ERK Pathway Exhibits Properties of a Negative Feedback Amplifier , 2010, Science Signaling.

[90]  D. Barford,et al.  Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. , 2005, Molecular cell.

[91]  C. Robert,et al.  RAF inhibition and induction of cutaneous squamous cell carcinoma , 2011, Current opinion in oncology.

[92]  R. Davis,et al.  Isolation and characterization of two growth factor-stimulated protein kinases that phosphorylate the epidermal growth factor receptor at threonine 669. , 1991, The Journal of biological chemistry.

[93]  M. Therrien,et al.  Regulation of RAF protein kinases in ERK signalling , 2015, Nature Reviews Molecular Cell Biology.

[94]  R. Huganir,et al.  MAPK cascade signalling and synaptic plasticity , 2004, Nature Reviews Neuroscience.

[95]  Matthew Freeman,et al.  Sprouty, an Intracellular Inhibitor of Ras Signaling , 1999, Cell.

[96]  R. Bernards,et al.  Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.

[97]  R. Weiss,et al.  MEK inhibition augments Raf activity, but has variable effects on mitogenesis, in vascular smooth muscle cells. , 1998, American journal of physiology. Cell physiology.

[98]  N. Papalopulu,et al.  Characterisation of a new regulator of BDNF signalling, Sprouty3, involved in axonal morphogenesis in vivo , 2010, Development.

[99]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[100]  Wendell A Lim,et al.  Scaffolds: interaction platforms for cellular signalling circuits. , 2009, Trends in cell biology.

[101]  R. Nadeau,et al.  Sprouty Genes Are Expressed in Osteoblasts and Inhibit Fibroblast Growth Factor-Mediated Osteoblast Responses , 2006, Calcified Tissue International.

[102]  The developing story of Sprouty and cancer , 2014, Cancer and Metastasis Reviews.

[103]  A. Ullrich,et al.  EGFR and FGFR Signaling through FRS2 Is Subject to Negative Feedback Control by ERK1/2 , 2003, Biological chemistry.

[104]  Christopher J. Staples,et al.  Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter , 2008, The Biochemical journal.

[105]  Min Han,et al.  The C. elegans ksr-1 gene encodes a novel raf-related kinase involved in Ras-mediated signal transduction , 1995, Cell.

[106]  N. Hacohen,et al.  Sprouty: a common antagonist of FGF and EGF signaling pathways in Drosophila. , 1999, Development.

[107]  D. Polsky,et al.  Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. , 2003, Cancer research.

[108]  Marcus C. Ravnan,et al.  Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. , 2012, Clinical therapeutics.

[109]  J. Otlewski,et al.  ERK-Mediated Phosphorylation of Fibroblast Growth Factor Receptor 1 on Ser777 Inhibits Signaling , 2013, Science Signaling.

[110]  B. Taylor,et al.  Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. , 2014, Cancer research.

[111]  Xiwen Ma,et al.  Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. , 2015, Cancer cell.

[112]  D. Schadendorf,et al.  A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. , 2013, Cancer discovery.

[113]  S. Estrem,et al.  Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma* , 2012, The Journal of Biological Chemistry.

[114]  Giulio Superti‐Furga,et al.  Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation , 1999, The EMBO journal.

[115]  L. Fattore,et al.  Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies , 2013, Journal of Translational Medicine.

[116]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[117]  H. Horvitz,et al.  The ksr-1 gene encodes a novel protein kinase involved in Ras-mediated signaling in C. elegans , 1995, Cell.

[118]  Deborah K. Morrison,et al.  Signaling dynamics of the KSR1 scaffold complex , 2009, Proceedings of the National Academy of Sciences.

[119]  J. Parsons,et al.  PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation , 2003, The Journal of cell biology.

[120]  S. Chandarlapaty,et al.  Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. , 2012, Cancer cell.

[121]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[122]  M. Berger,et al.  Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients , 2015, Clinical Cancer Research.

[123]  S. Keyse,et al.  Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. , 2000, Current opinion in cell biology.

[124]  J. Licht,et al.  Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. , 2006, Trends in cell biology.

[125]  N. Hynes,et al.  Negative Modulation of Membrane Localization of the Raf-1 Protein Kinase by Hyperphosphorylation* , 1997, The Journal of Biological Chemistry.

[126]  W. Kolch,et al.  Regulation and Role of Raf-1/B-Raf Heterodimerization , 2006, Molecular and Cellular Biology.

[127]  Carlotta Costa,et al.  MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. , 2012, Cancer research.

[128]  G. Guy,et al.  Sprouty proteins: modified modulators, matchmakers or missing links? , 2009, The Journal of endocrinology.

[129]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[130]  Dirk Schadendorf,et al.  Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. , 2014, European journal of cancer.

[131]  D. Morrison,et al.  Identification of B-KSR1, a Novel Brain-Specific Isoform of KSR1 That Functions in Neuronal Signaling , 2000, Molecular and Cellular Biology.

[132]  P. Dent,et al.  Mitogen-activated protein kinase kinase 1 (MKK1) is negatively regulated by threonine phosphorylation , 1994, Molecular and cellular biology.

[133]  G. Guy,et al.  Sprouty2 Inhibits the Ras/MAP Kinase Pathway by Inhibiting the Activation of Raf* , 2002, The Journal of Biological Chemistry.